Funded Grants

Grants awarded in the current fiscal year and carried over from prior fiscal years.

PI Name	PI Organization	Title	Grant Number	Initiative	Program Official Sort descending
Tennis, Meredith A	University Of Colorado Denver United States	Persistence and regression in lung premalignant lesions	5R01CA289576-02		Malgorzata Wojtowicz, M.D.
Ondrey, Frank G.	University Of Minnesota United States	Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia	5R01CA254270-04	PAR-21-035 (R01 Clinical Trial Required)	Malgorzata Wojtowicz, M.D.
Majumder, Shounak	Mayo Clinic Rochester United States	Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer	5U01CA210138-09		Matthew Young, Ph.D.
Cocucci, Emanuele	Ohio State University United States	A SYNTHETIC BIOMARKER TO UNIVERSALLY ASSESS THE RELATIVE CONTRIBUTION OF HEATHY AND CANCEROUS TISSUE TO CIRCULATING EV POOL	5R01CA270251-04	PAR-20-053 (R01 Clinical Trial Not Allowed)	Matthew Young, Ph.D.
Ghosh, Jayashri	Temple Univ Of The Commonwealth United States	Development of blood-based methylation biomarkers for CRC risk prediction	5R01CA281948-03		Matthew Young, Ph.D.
Kirkwood, Kimberly Saunders	University Of California, San Francisco United States	Using microvolumetric cyst fluid proteolysis for early detection of pancreatic cancer	5U01CA282269-02		Matthew Young, Ph.D.
Sen, Subrata	University Of Tx Md Anderson Can Ctr United States	Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer	5U01CA214263-07		Matthew Young, Ph.D.
Zhu, Yazhen	University Of California Los Angeles United States	Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular Carcinoma	5R01CA255727-05		Matthew Young, Ph.D.
Wolpin, Brian Matthew	Dana-Farber Cancer Inst United States	Altered metabolism and machine learning for pancreatic cancer early detection	5U01CA210171-09		Matthew Young, Ph.D.
Stachler, Matthew D	University Of California, San Francisco United States	Optimization and validation of a biomarker panel for risk stratification in Barrett's esophagus	5R37CA269649-04	PA-20-185 (Parent R01 Clinical Trial Not Allowed)	Matthew Young, Ph.D.